Cargando…
A longitudinal study on quality of life along the spectrum of Alzheimer’s disease
BACKGROUND: Quality of life (QoL) is an important outcome from the perspective of patients and their caregivers, in both dementia and pre-dementia stages. Yet, little is known about the long-term changes in QoL over time. We aimed to compare the trajectories of QoL between amyloid-positive and amylo...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476356/ https://www.ncbi.nlm.nih.gov/pubmed/36109800 http://dx.doi.org/10.1186/s13195-022-01075-8 |
_version_ | 1784790118089883648 |
---|---|
author | Mank, Arenda Rijnhart, Judith J. M. van Maurik, Ingrid S. Jönsson, Linus Handels, Ron Bakker, Els D. Teunissen, Charlotte E. van Berckel, Bart N. M. van Harten, Argonde C. Berkhof, Johannes van der Flier, Wiesje M. |
author_facet | Mank, Arenda Rijnhart, Judith J. M. van Maurik, Ingrid S. Jönsson, Linus Handels, Ron Bakker, Els D. Teunissen, Charlotte E. van Berckel, Bart N. M. van Harten, Argonde C. Berkhof, Johannes van der Flier, Wiesje M. |
author_sort | Mank, Arenda |
collection | PubMed |
description | BACKGROUND: Quality of life (QoL) is an important outcome from the perspective of patients and their caregivers, in both dementia and pre-dementia stages. Yet, little is known about the long-term changes in QoL over time. We aimed to compare the trajectories of QoL between amyloid-positive and amyloid-negative SCD or MCI patients and to evaluate QoL trajectories along the Alzheimer’s disease (AD) continuum of cognitively normal to dementia. METHODS: We included longitudinal data of 447 subjective cognitive decline (SCD), 276 mild cognitive impairment (MCI), and 417 AD dementia patients from the Amsterdam Dementia Cohort. We compared QoL trajectories (EQ-5D and visual analog scale (VAS)) between (1) amyloid-positive and amyloid-negative SCD or MCI patients and (2) amyloid-positive SCD, MCI, and dementia patients with linear mixed-effect models. The models were adjusted for age, sex, Charlson Comorbidity Index (CCI), education, and EQ-5D scale (3 or 5 level). RESULTS: In SCD, amyloid-positive participants had a higher VAS at baseline but showed a steeper decline over time in EQ-5D and VAS than amyloid-negative participants. Also, in MCI, amyloid-positive patients had higher QoL at baseline but subsequently showed a steeper decline in QoL over time compared to amyloid-negative patients. When we compared amyloid-positive patients along the Alzheimer continuum, we found no difference between SCD, MCI, or dementia in baseline QoL, but QoL decreased at a faster rate in the dementia stage compared with the of SCD and MCI stages. CONCLUSIONS: QoL decreased at a faster rate over time in amyloid-positive SCD or MCI patients than amyloid-negative patients. QoL decreases over time along the entire AD continuum of SCD, MCI and dementia, with the strongest decrease in dementia patients. Knowledge of QoL trajectories is essential for the future evaluation of treatments in AD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-022-01075-8. |
format | Online Article Text |
id | pubmed-9476356 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-94763562022-09-16 A longitudinal study on quality of life along the spectrum of Alzheimer’s disease Mank, Arenda Rijnhart, Judith J. M. van Maurik, Ingrid S. Jönsson, Linus Handels, Ron Bakker, Els D. Teunissen, Charlotte E. van Berckel, Bart N. M. van Harten, Argonde C. Berkhof, Johannes van der Flier, Wiesje M. Alzheimers Res Ther Research BACKGROUND: Quality of life (QoL) is an important outcome from the perspective of patients and their caregivers, in both dementia and pre-dementia stages. Yet, little is known about the long-term changes in QoL over time. We aimed to compare the trajectories of QoL between amyloid-positive and amyloid-negative SCD or MCI patients and to evaluate QoL trajectories along the Alzheimer’s disease (AD) continuum of cognitively normal to dementia. METHODS: We included longitudinal data of 447 subjective cognitive decline (SCD), 276 mild cognitive impairment (MCI), and 417 AD dementia patients from the Amsterdam Dementia Cohort. We compared QoL trajectories (EQ-5D and visual analog scale (VAS)) between (1) amyloid-positive and amyloid-negative SCD or MCI patients and (2) amyloid-positive SCD, MCI, and dementia patients with linear mixed-effect models. The models were adjusted for age, sex, Charlson Comorbidity Index (CCI), education, and EQ-5D scale (3 or 5 level). RESULTS: In SCD, amyloid-positive participants had a higher VAS at baseline but showed a steeper decline over time in EQ-5D and VAS than amyloid-negative participants. Also, in MCI, amyloid-positive patients had higher QoL at baseline but subsequently showed a steeper decline in QoL over time compared to amyloid-negative patients. When we compared amyloid-positive patients along the Alzheimer continuum, we found no difference between SCD, MCI, or dementia in baseline QoL, but QoL decreased at a faster rate in the dementia stage compared with the of SCD and MCI stages. CONCLUSIONS: QoL decreased at a faster rate over time in amyloid-positive SCD or MCI patients than amyloid-negative patients. QoL decreases over time along the entire AD continuum of SCD, MCI and dementia, with the strongest decrease in dementia patients. Knowledge of QoL trajectories is essential for the future evaluation of treatments in AD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-022-01075-8. BioMed Central 2022-09-15 /pmc/articles/PMC9476356/ /pubmed/36109800 http://dx.doi.org/10.1186/s13195-022-01075-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Mank, Arenda Rijnhart, Judith J. M. van Maurik, Ingrid S. Jönsson, Linus Handels, Ron Bakker, Els D. Teunissen, Charlotte E. van Berckel, Bart N. M. van Harten, Argonde C. Berkhof, Johannes van der Flier, Wiesje M. A longitudinal study on quality of life along the spectrum of Alzheimer’s disease |
title | A longitudinal study on quality of life along the spectrum of Alzheimer’s disease |
title_full | A longitudinal study on quality of life along the spectrum of Alzheimer’s disease |
title_fullStr | A longitudinal study on quality of life along the spectrum of Alzheimer’s disease |
title_full_unstemmed | A longitudinal study on quality of life along the spectrum of Alzheimer’s disease |
title_short | A longitudinal study on quality of life along the spectrum of Alzheimer’s disease |
title_sort | longitudinal study on quality of life along the spectrum of alzheimer’s disease |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476356/ https://www.ncbi.nlm.nih.gov/pubmed/36109800 http://dx.doi.org/10.1186/s13195-022-01075-8 |
work_keys_str_mv | AT mankarenda alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT rijnhartjudithjm alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT vanmaurikingrids alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT jonssonlinus alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT handelsron alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT bakkerelsd alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT teunissencharlottee alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT vanberckelbartnm alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT vanhartenargondec alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT berkhofjohannes alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT vanderflierwiesjem alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT mankarenda longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT rijnhartjudithjm longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT vanmaurikingrids longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT jonssonlinus longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT handelsron longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT bakkerelsd longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT teunissencharlottee longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT vanberckelbartnm longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT vanhartenargondec longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT berkhofjohannes longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT vanderflierwiesjem longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease |